Aggressive Squamous Cell Carcinoma in a Transplant Recipient

Main Article Content

Grace Boyd
University of California, Los Angeles, Department of Medicine, Division of Dermatology, Los Angeles, California, USA

Jessica Terrell
University of California, Los Angeles, Department of Medicine, Division of Dermatology, Los Angeles, California, USA

Dr. Michael O. Nguyen
University of California, Los Angeles, Department of Medicine, Division of Dermatology, Los Angeles, California, USA

Keywords

Cutaneous Squamous Cell Carcinoma, Transplant, Immunosuppression

References

1. Bibee K, Swartz A, Sridharan S, Kurten CHL, Wessel CB, Skinner H, Zandberg DP. Cutaneous squamous cell carcinoma in the organ transplant recipient. Oral Oncol. 2020;104:104609. doi:10.1016/j.oraloncology.2019.104562

2. O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263-279. doi:10.1016/j.jaad.2010.11.063.

3. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J; TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329-339.
doi:10.1056/NEJMoa1204166.

4. Bhullar S, Christensen SR. Effectiveness of acitretin for skin cancer prevention in immunosuppressed and nonimmunosuppressed patients: a retrospective cohort study. J Am Acad Dermatol. 2024;90(4):709-717. doi:10.1016/j.jaad.2023.11.034.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/g145fw95

Article Details

How to Cite
1.
Aggressive Squamous Cell Carcinoma in a Transplant Recipient. J of Skin. 2025;9(6):2799-2802. doi:10.25251/g145fw95
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
SKINmages: Clinical Images in Dermatology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.